Novo Nordisk A/S (NYSE:NVO) Given Average Recommendation of “Hold” by Brokerages

Novo Nordisk A/S (NYSE:NVO) has been given an average rating of “Hold” by the twenty-three analysts that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $65.5625.

Several equities research analysts have recently issued reports on NVO shares. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Wolfe Research began coverage on Novo Nordisk A/S in a report on Thursday, March 26th. They set a “peer perform” rating for the company. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Zacks Research downgraded Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday. Finally, Weiss Ratings cut Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, April 22nd.

Novo Nordisk A/S Price Performance

NVO opened at $51.50 on Friday. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $71.79. The firm has a 50-day moving average of $46.01 and a 200 day moving average of $45.79. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The firm has a market cap of $229.96 billion, a P/E ratio of 12.09, a PEG ratio of 4.61 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The business had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. On average, research analysts expect that Novo Nordisk A/S will post 3.38 EPS for the current year.

Hedge Funds Weigh In On Novo Nordisk A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Revolve Wealth Partners LLC lifted its position in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after acquiring an additional 200 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Novo Nordisk A/S by 21.0% in the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after purchasing an additional 10,758 shares during the last quarter. Sivia Capital Partners LLC raised its stake in Novo Nordisk A/S by 18.2% in the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after purchasing an additional 1,587 shares in the last quarter. Invesco Ltd. lifted its position in Novo Nordisk A/S by 26.3% during the second quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock valued at $28,967,000 after purchasing an additional 87,467 shares during the last quarter. Finally, Gamco Investors INC. ET AL bought a new stake in Novo Nordisk A/S during the second quarter valued at approximately $314,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: The European Commission approved Novo Nordisk’s once-daily oral Wegovy pill for obesity, making it the first GLP-1 tablet cleared for weight management in the EU and expanding the company’s addressable market. Reuters article on EU approval
• Positive Sentiment: Multiple reports said the oral Wegovy approval could help Novo Nordisk extend its lead over Eli Lilly in obesity treatment, reinforcing optimism around the company’s long-term growth in diabetes and weight-loss therapies. Pharmaceutical Technology article on competition with Lilly
• Positive Sentiment: Analysts and market commentary pointed to improved growth expectations and higher fair value estimates after the approval, signaling that sentiment around Novo’s obesity pipeline has improved. Yahoo Finance article on fair value estimate
• Neutral Sentiment: Novo also announced a new Phase 3 heart failure–obesity trial, which supports its cardiometabolic strategy but is still early-stage and unlikely to affect near-term results. TipRanks article on trial update
• Negative Sentiment: Separate news that Sun Pharma won approval in South Africa for a generic version of semaglutide highlights ongoing competitive and copycat-drug pressure on Novo Nordisk’s key products. Reuters article on generic Ozempic approval
• Negative Sentiment: Zacks Research downgraded Novo Nordisk from hold to strong sell, showing that not all analysts are convinced the stock’s recent strength will continue. Tickerreport article on downgrade

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.